• Jahnvi Srivastava
• Santoshi Shah
• Dr.Shivanand Patil

Objective: Irresistible bacterial infectious diseases pose a serious threat to human health, and social workers' failure to act to prevent infections may encourage epidemics and the quick spread of infections among the majority of people. That the need for develop the different approach or method to enhance effect of rifampicin as anti-microbial and reduce the bacterial effect with use liposome and TPGS. Material method: A thin film approach was used to generate RIF-LIPO and RIF-LIPO-TPGS, were dissolved in a small volume of a 3:1 v/v methanol and chloroform combination. Rota evaporator used solvent evaporation under vacuum to cast the lipid layer on the inner surface of the flask centrifuge with 15 min. at 3000 rpm. And identification of rifampicin TPGS liposomes with the help of UV, FTIR analysis, XRD, entrapment efficiency. Main target to check the anti-microbial resistance of rifampicin loaded liposome with TPGS. That had already been pre-treated. The formulations placed inside the barrier array were placed in a 37°C-controlled release medium. At intervals of 1, 2, 4, 8, 12, 24, 48, and 72 hours, aliquots of the samples (1.0 mL) were taken out and the same volume (1.0 mL) of new release medium was added to maintain the sink condition. Result: FTIR of drug excipients interaction and liposomal formulation depicts no chemical incompatibility were taken place, as no significant change in the vibrational frequency of Rifampicin (RIF) in liposomes were observed.At their respective MICs (1.56 g/ml, 1.56 g/ml, and 1.56 g/m.), Control, Rifampicin, Rifampicin -liposome, and Rifampicin -TPGS- liposome displayed 1244, 1253, 1295, and 27228. demonstrating the superiority of the Rifampicin -TPGS- liposome in terms of enhancing the antibacterial activity of free Rifampicin and Rifampicin -liposome. Utilizing a dialysis approach, we studied RIF releases kinetics in PBS as a diffusion fluid around 37.1°C to try to decipher that in-vitro RIF releasing behavior from RIF-LIPO and RIF-TPGS-LIPO vesicles. Over the course of 72 hours, the amount of release of liposomes packed by Rifampicin or liposomes that used It TPGS, or was investigated. Rifampicin TPGS liposomes demonstrated about 56+2.7% of the medication release in 72 hours, while more than 73+2.5% of Rifampicin was released in that time.

quality by Design (QbD); drug delivery; liposomes; nano-pharmaceuticals; nanomedicine.

"Integrated Quality by Design Strategy for the Development of TPGS-Loaded Liposomal Formulations Targeting Antimicrobial Resistance", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 6, page no.d450-d459, June-2024, Available :http://www.jetir.org/papers/JETIR2406355.pdf

"Integrated Quality by Design Strategy for the Development of TPGS-Loaded Liposomal Formulations Targeting Antimicrobial Resistance", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 6, page no. ppd450-d459, June-2024, Available at : http://www.jetir.org/papers/JETIR2406355.pdf